Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 8 patents granted in the last 365 days
H. Lundbeck A/S has 3 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 3 distinct examiners but 2 distinct art units, showing examiner dispersion across a narrower set of technical examination groups.
LEE, CHIHYI NMN is the busiest examiner, with 1 pending matter. Counsel should coordinate across the shared art-unit landscape while retaining separate response strategies for the individual examiner assignments.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
| No statute on record | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LEE, CHIHYI NMN | 1 | 33.3% | +61.1% |
| PAK, MICHAEL D | 1 | 58.6% | +29.9% |
| CHERNYSHEV, OLGA N | 1 | 54.5% | +34.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18679695 | SPIROMACROCYCLIC OREXIN 2 RECEPTOR AGONISTS | LEE, CHIHYI NMN | — |
| 18683790 | TREATMENT OF CLUSTER HEADACHE USING ANTI-CGRP ANTIBODIES | PAK, MICHAEL D | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18679695 | SPIROMACROCYCLIC OREXIN 2 RECEPTOR AGONISTS | LEE, CHIHYI NMN | — |
| 18683790 | TREATMENT OF CLUSTER HEADACHE USING ANTI-CGRP ANTIBODIES | PAK, MICHAEL D | — |
| 18511241 | TREATMENT OF MEDICATION OVERUSE HEADACHE USING ANTI-CGRP OR ANTI-CGRP-R ANTIBODIES | CHERNYSHEV, OLGA N | — |
| Art Unit | Apps |
|---|---|
| 1628 | 1 |
| 1675 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18679695 | SPIROMACROCYCLIC OREXIN 2 RECEPTOR AGONISTS | LEE, CHIHYI NMN | 1628 | §101§112Other | Non-Final OA | — | Pending | May 31, 2024 |
| 18683790 | TREATMENT OF CLUSTER HEADACHE USING ANTI-CGRP ANTIBODIES | PAK, MICHAEL D | — | §103§112 | Non-Final OA | — | Pending | Feb 15, 2024 |
| 18511241 | TREATMENT OF MEDICATION OVERUSE HEADACHE USING ANTI-CGRP OR ANTI-CGRP-R ANTIBODIES | CHERNYSHEV, OLGA N | 1675 | Other | Final Rejection | — | Pending | Nov 16, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialH. Lundbeck A/S has 3 pending office actions as of October 2026, spread across 2 art units and 3 examiners.
Chihyi Nmn Lee has the most, with 1 of H. Lundbeck A/S's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
